CaMKIγ inhibitors are a class of chemical compounds that specifically target and inhibit the activity of CaMKIγ, a member of the Ca2+/calmodulin-dependent protein kinase I (CaMKI) family. CaMKIγ plays a crucial role in regulating a variety of cellular processes, including signal transduction, gene expression, and cytoskeletal dynamics, all of which are influenced by calcium signaling. The enzyme's activity is tightly regulated by its interaction with the calcium-bound protein calmodulin, which activates CaMKIγ by binding to its regulatory domain. By inhibiting CaMKIγ, these compounds disrupt the kinase's ability to phosphorylate its downstream substrates, which can lead to alterations in calcium-dependent cellular pathways.
The design of CaMKIγ inhibitors typically focuses on blocking either the enzyme's active site or its interaction with calmodulin. Inhibitors that target the active site often mimic ATP or other substrates, competing with these molecules for binding to the kinase and preventing phosphorylation reactions. Other inhibitors might bind to the calmodulin-binding domain, preventing the necessary activation of CaMKIγ by calcium/calmodulin. The development of these inhibitors involves a combination of high-throughput screening, molecular docking studies, and structure-activity relationship (SAR) analysis to identify compounds with high specificity and affinity for CaMKIγ. Once candidate inhibitors are identified, they are synthesized using organic chemistry techniques and further characterized through biochemical assays, such as kinase activity assays, to measure their effectiveness. Additionally, structural biology tools like X-ray crystallography and molecular dynamics simulations are often employed to provide detailed insights into how these inhibitors interact with CaMKIγ, aiding in the refinement of their design for optimal inhibitory activity. Through these methods, CaMKIγ inhibitors offer valuable tools for understanding the regulation of calcium-dependent signaling pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Nimodipine | 66085-59-4 | sc-201464 sc-201464A | 100 mg 1 g | $60.00 $301.00 | 2 | |
L-type calcium channel blocker, can indirectly affect calcium signaling pathways involving CaMKIγ. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $58.00 $170.00 | 15 | |
Another L-type calcium channel blocker, potentially influencing CaMKIγ activity via calcium modulation. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $73.00 $163.00 | 2 | |
L-type calcium channel blocker, may modulate calcium signaling affecting CaMKIγ. | ||||||
Calmidazolium chloride | 57265-65-3 | sc-201494 sc-201494A | 10 mg 50 mg | $153.00 $600.00 | 27 | |
Calmodulin antagonist, can indirectly influence CaMKIγ activity by modulating calmodulin. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $163.00 $300.00 $1642.00 | 18 | |
Calmodulin inhibitor, potentially affecting CaMKIγ function. | ||||||
KN-93 | 139298-40-1 | sc-202199 | 1 mg | $178.00 | 25 | |
Inhibits CaMKII, and may have off-target effects on CaMKIγ. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Calcium channel blocker, can indirectly affect CaMKIγ through calcium signaling modulation. | ||||||
Ophiobolin A | 4611-05-6 | sc-202266 sc-202266A sc-202266B | 100 µg 1 mg 5 mg | $43.00 $245.00 $714.00 | 7 | |
Inhibitor of calmodulin activity, potentially impacting CaMKIγ. | ||||||
Fenvalerate | 51630-58-1 | sc-24014 sc-24014A | 25 mg 100 mg | $78.00 $226.00 | 2 | |
Modulates calcium channels, potentially influencing pathways involving CaMKIγ. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Calcium channel blocker, might have an indirect effect on CaMKIγ activity. |